Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 47.96
NVO's Cash to Debt is ranked higher than
72% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. NVO: 47.96 )
NVO' s 10-Year Cash to Debt Range
Min: 0.29   Max: No Debt
Current: 47.96

Equity to Asset 0.53
NVO's Equity to Asset is ranked higher than
65% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NVO: 0.53 )
NVO' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.73
Current: 0.53

0.51
0.73
Interest Coverage 572.60
NVO's Interest Coverage is ranked higher than
58% of the 576 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NVO: 572.60 )
NVO' s 10-Year Interest Coverage Range
Min: 5.69   Max: 572.6
Current: 572.6

5.69
572.6
F-Score: 8
Z-Score: 18.76
M-Score: -2.60
WACC vs ROIC
12.28%
91.32%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 38.05
NVO's Operating margin (%) is ranked higher than
96% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. NVO: 38.05 )
NVO' s 10-Year Operating margin (%) Range
Min: 10.5   Max: 37.77
Current: 38.05

10.5
37.77
Net-margin (%) 30.27
NVO's Net-margin (%) is ranked higher than
95% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. NVO: 30.27 )
NVO' s 10-Year Net-margin (%) Range
Min: 11.39   Max: 30.13
Current: 30.27

11.39
30.13
ROE (%) 68.47
NVO's ROE (%) is ranked higher than
99% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. NVO: 68.47 )
NVO' s 10-Year ROE (%) Range
Min: 11.85   Max: 60.54
Current: 68.47

11.85
60.54
ROA (%) 38.62
NVO's ROA (%) is ranked higher than
98% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. NVO: 38.62 )
NVO' s 10-Year ROA (%) Range
Min: 8.5   Max: 37.03
Current: 38.62

8.5
37.03
ROC (Joel Greenblatt) (%) 131.48
NVO's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. NVO: 131.48 )
NVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.89   Max: 126.76
Current: 131.48

6.89
126.76
Revenue Growth (3Y)(%) 14.30
NVO's Revenue Growth (3Y)(%) is ranked higher than
85% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. NVO: 14.30 )
NVO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0.3   Max: 23
Current: 14.3

0.3
23
EBITDA Growth (3Y)(%) 19.00
NVO's EBITDA Growth (3Y)(%) is ranked higher than
88% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. NVO: 19.00 )
NVO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 8.4   Max: 25.7
Current: 19

8.4
25.7
EPS Growth (3Y)(%) 23.90
NVO's EPS Growth (3Y)(%) is ranked higher than
89% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. NVO: 23.90 )
NVO' s 10-Year EPS Growth (3Y)(%) Range
Min: 10.3   Max: 29.7
Current: 23.9

10.3
29.7
» NVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NVO Guru Trades in Q1 2014

Ken Fisher 13,631,979 sh (+0.58%)
Jim Simons 16,079,800 sh (-1.46%)
Tom Gayner 1,075,000 sh (-2.8%)
Mario Gabelli 7,665 sh (-10.04%)
Ruane Cunniff 242,630 sh (-21.98%)
Steven Cohen 9,962 sh (-36.57%)
Murray Stahl 7,740 sh (-80%)
» More
Q2 2014

NVO Guru Trades in Q2 2014

Jim Simons 16,953,000 sh (+5.43%)
Ken Fisher 13,741,529 sh (+0.8%)
Murray Stahl 7,740 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Mario Gabelli 7,620 sh (-0.59%)
Ruane Cunniff 160,492 sh (-33.85%)
» More
Q3 2014

NVO Guru Trades in Q3 2014

Murray Stahl 7,740 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Ken Fisher 13,385,913 sh (-2.59%)
Jim Simons 16,106,100 sh (-5%)
Mario Gabelli 6,720 sh (-11.81%)
Ruane Cunniff 75,642 sh (-52.87%)
» More
Q4 2014

NVO Guru Trades in Q4 2014

Steven Cohen 481,700 sh (New)
Ruane Cunniff 82,192 sh (+8.66%)
Murray Stahl 7,907 sh (+2.16%)
Mario Gabelli 6,720 sh (unchged)
Tom Gayner 1,075,000 sh (unchged)
Ken Fisher 13,039,648 sh (-2.59%)
Jim Simons 15,614,600 sh (-3.05%)
» More
» Details

Insider Trades

Latest Guru Trades with NVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ruane Cunniff 2014-09-30 Reduce -52.87%0.02%$43.9 - $49.03 $ 46.842%75642
Ruane Cunniff 2014-06-30 Reduce -33.85%0.02%$42.28 - $46.52 $ 46.846%160492
Ruane Cunniff 2014-03-31 Reduce -21.98%0.01%$36.722 - $48.23 $ 46.8410%242630
Ruane Cunniff 2013-12-31 Add 58.71%0.02%$32.72 - $36.886 $ 46.8434%62194
Ruane Cunniff 2013-06-30 New Buy0.04%$30.11 - $35.33 $ 46.8441%34640
Mario Gabelli 2013-03-31 Reduce -60.32%$32.24 - $38.86 $ 46.8434%1734
John Hussman 2012-09-30 Sold Out 0.01%$28.83 - $32.15 $ 46.8453%0
Ken Fisher 2012-06-30 Add 519.97%1.01%$25.98 - $30.38 $ 46.8465%2786828
John Hussman 2012-03-31 Reduce -40%$23.09 - $28.94 $ 46.8489%3000
Mario Gabelli 2011-12-31 Add 66.87%$18.92 - $23.05 $ 46.84118%5590
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 32.10
NVO's P/E(ttm) is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 32.10 )
NVO' s 10-Year P/E(ttm) Range
Min: 12.11   Max: 32.52
Current: 32.1

12.11
32.52
Forward P/E 20.96
NVO's Forward P/E is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 20.96 )
N/A
PE(NRI) 32.10
NVO's PE(NRI) is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 32.10 )
NVO' s 10-Year PE(NRI) Range
Min: 12.09   Max: 32.52
Current: 32.1

12.09
32.52
P/B 22.02
NVO's P/B is ranked higher than
59% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. NVO: 22.02 )
NVO' s 10-Year P/B Range
Min: 3.41   Max: 22.31
Current: 22.02

3.41
22.31
P/S 9.71
NVO's P/S is ranked higher than
83% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. NVO: 9.71 )
NVO' s 10-Year P/S Range
Min: 2.81   Max: 9.84
Current: 9.71

2.81
9.84
PFCF 31.88
NVO's PFCF is ranked higher than
96% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 31.88 )
NVO' s 10-Year PFCF Range
Min: 12.1   Max: 47.01
Current: 31.88

12.1
47.01
POCF 28.00
NVO's POCF is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 28.00 )
NVO' s 10-Year POCF Range
Min: 7.96   Max: 29.8
Current: 28

7.96
29.8
EV-to-EBIT 25.13
NVO's EV-to-EBIT is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 25.13 )
NVO' s 10-Year EV-to-EBIT Range
Min: 9.1   Max: 26.1
Current: 25.13

9.1
26.1
PEG 1.43
NVO's PEG is ranked higher than
98% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 1.43 )
NVO' s 10-Year PEG Range
Min: 0.54   Max: 1.66
Current: 1.43

0.54
1.66
Shiller P/E 45.37
NVO's Shiller P/E is ranked higher than
96% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 45.37 )
NVO' s 10-Year Shiller P/E Range
Min: 18.94   Max: 45.93
Current: 45.37

18.94
45.93
Current Ratio 1.37
NVO's Current Ratio is ranked higher than
56% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. NVO: 1.37 )
NVO' s 10-Year Current Ratio Range
Min: 1.31   Max: 2.45
Current: 1.37

1.31
2.45
Quick Ratio 1.00
NVO's Quick Ratio is ranked higher than
55% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. NVO: 1.00 )
NVO' s 10-Year Quick Ratio Range
Min: 0.92   Max: 1.91
Current: 1

0.92
1.91
Days Inventory 267.55
NVO's Days Inventory is ranked higher than
80% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 267.55 )
NVO' s 10-Year Days Inventory Range
Min: 201.98   Max: 417.53
Current: 267.55

201.98
417.53
Days Sales Outstanding 45.94
NVO's Days Sales Outstanding is ranked higher than
84% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. NVO: 45.94 )
NVO' s 10-Year Days Sales Outstanding Range
Min: 45.09   Max: 152.61
Current: 45.94

45.09
152.61

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.77
NVO's Dividend Yield is ranked higher than
74% of the 198 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. NVO: 1.77 )
NVO' s 10-Year Dividend Yield Range
Min: 0.79   Max: 2.47
Current: 1.77

0.79
2.47
Dividend Payout 0.45
NVO's Dividend Payout is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 0.45 )
NVO' s 10-Year Dividend Payout Range
Min: 0.51   Max: 1.85
Current: 0.45

0.51
1.85
Dividend growth (3y) 49.40
NVO's Dividend growth (3y) is ranked higher than
97% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 12.10 vs. NVO: 49.40 )
NVO' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 49.4
Current: 49.4

0
49.4
Yield on cost (5-Year) 7.27
NVO's Yield on cost (5-Year) is ranked higher than
99% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 1.39 vs. NVO: 7.27 )
NVO' s 10-Year Yield on cost (5-Year) Range
Min: 3.19   Max: 9.97
Current: 7.27

3.19
9.97
Share Buyback Rate 2.70
NVO's Share Buyback Rate is ranked higher than
98% of the 886 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. NVO: 2.70 )
NVO' s 10-Year Share Buyback Rate Range
Min: 3   Max: 0.4
Current: 2.7

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 106.62
NVO's Price/Net Current Asset Value is ranked lower than
54% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 36.79 vs. NVO: 106.62 )
NVO' s 10-Year Price/Net Current Asset Value Range
Min: 11.79   Max: 140.23
Current: 106.62

11.79
140.23
Price/Tangible Book 22.87
NVO's Price/Tangible Book is ranked higher than
64% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. NVO: 22.87 )
NVO' s 10-Year Price/Tangible Book Range
Min: 3.15   Max: 17.72
Current: 22.87

3.15
17.72
Price/DCF (Projected) 4.01
NVO's Price/DCF (Projected) is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 4.01 )
NVO' s 10-Year Price/DCF (Projected) Range
Min: 1.3   Max: 22.47
Current: 4.01

1.3
22.47
Price/Median PS Value 2.01
NVO's Price/Median PS Value is ranked higher than
75% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. NVO: 2.01 )
NVO' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 1.8
Current: 2.01

0.16
1.8
Price/Peter Lynch Fair Value 1.52
NVO's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 1.52 )
NVO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.07   Max: 1.36
Current: 1.52

0.07
1.36
Price/Graham Number 5.72
NVO's Price/Graham Number is ranked higher than
91% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NVO: 5.72 )
NVO' s 10-Year Price/Graham Number Range
Min: 1.6   Max: 5.11
Current: 5.72

1.6
5.11
Earnings Yield (Greenblatt) 4.00
NVO's Earnings Yield (Greenblatt) is ranked higher than
95% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. NVO: 4.00 )
NVO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.8   Max: 11
Current: 4

3.8
11
Forward Rate of Return (Yacktman) 23.32
NVO's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 15.72 vs. NVO: 23.32 )
NVO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.7   Max: 36.1
Current: 23.32

1.7
36.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMGN, GILD, BIIB, CELG, CMXHY » details
Traded in other countries:0QIU.UK, NOVO B.Denmark, NONOF.USA, NOVA.Germany, NOVC.Germany, NOVOB.Switzerland,
Novo-Nordisk A/S was incorporated on 28th November, 1931 in Denmark. It is a healthcare company that is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two business segments: diabetes care and biopharmaceuticals. The diabetes care segment covers insulins, GLP-1, other protein-related products which include glucagon, protein-related delivery systems and needles, obesity and oral antidiabetic drugs. The biopharmaceuticals segment covers the therapy areas of haemophilia care, growth hormone therapy, hormone replacement therapy and inflammation.
» More Articles for NVO

Headlines

Articles On GuruFocus.com
To Reinvest or Not Reinvest: That is the Question Feb 19 2015 
Guru Stocks at 52-Week Lows: BABA, NVO, PCLN, ING, EMR Feb 09 2015 
Examining The Three Largest Guru Portfolios Oct 24 2014 
Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20% Oct 01 2014 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Sep 02 2014 
Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Aug 23 2014 
GAMCO CIO Howard Ward on Reliable Consumer Stock Ideas Apr 09 2014 
Assessing the New Boss at National Oilwell Varco Mar 31 2014 

More From Other Websites
Novo Nordisk A/S gennemfører succesfuld børsnotering af NNIT A/S Mar 06 2015
Business Highlights Mar 05 2015
Novo Nordisk's Oral Semaglutide Positive in Diabetes Study - Analyst Blog Feb 23 2015
Novo Nordisk Pops On Successful Diabetes Drug Trial Feb 20 2015
Baxter Announces Positive Data for BAX 855; Competition Rife - Analyst Blog Feb 12 2015
On MannKind, Diabetics Have One Up On Wall Street Feb 06 2015
Novo Nordisk files annual report with the SEC Feb 05 2015
Sale of Seattle BioMed, Juno building sets Seattle price record Feb 03 2015
Novo-Nordisk As (NVO): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Feb 03 2015
Novo Nordisk's Q4 Earnings Rise Y/Y, Provides 2015 Outlook - Analyst Blog Feb 02 2015
Diabetics: Use Your Firsthand Experience To Beat Wall Street Jan 30 2015
Up to Speed: Peltz receives ammo in fight against DuPont (Video) Jan 28 2015
Afrezza Breathes Life Into MannKind Jan 27 2015
Novo Nordisk stock rises 3% Jan 26 2015
4 Stocks Spiking on Unusual Volume: Novo Nordisk and More Jan 26 2015
Novo Nordisk's Xultophy to Launch First in Switzerland - Analyst Blog Jan 20 2015
Three Companies That Should Benefit From a Stronger U.S. Dollar Jan 20 2015
CSE Enjoys Record Year in 2014, International Outreach and Trading Initiatives Help Shape Agenda for... Jan 14 2015
5 Obesity Stocks Investors Are Watching Jan 14 2015
Pharma Grows Itself a New Challenge -- Overheard Jan 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK